Taj Worldwide | Taj Group | Media | Career | FAQs | Feedback | contact us
 
Taj Logo
Powerful and effective
 
figure and reports
Quality Medicines Api Generic Manufacturing For Doctors Brands Newsroom
  figure reports  
  HOME >> Figure & Reports
Figure & Reports
 
 

 

 

Providing products and services to treat and monitor diseases is at the core of Taj Pharmaceutical's activities in all major therapeutic areas. We are concentrating our efforts especially on those areas, where there are important medical needs and where patients can benefit from an adequate treatment regimen. Our product range makes it possible to offer real improvements to doctors, hospitals and patients.

Focusing on prescription drugs, we currently engage in the following areas (amongst others):


For many of these areas and the corresponding indications, Taj Pharmaceuticals has provided a large range of therapeutic options. Please view a selection of major prescription drugs by accessing the current
Selected Products overview.

 

  TAJ PHARMACEUTICALS GROUP ANNUAL REPORT
  Annual Report 2011  (PDF, 5295Kb)  Annual Report 2011  
The above report is a comprehensive report on a company's activities throughout the preceding year. The report is intended to give shareholders and other interested people information about the company's activities and financial performance.
 
   
  ANNUAL SUSTAINABILITY REPORT - TAJ PHARMACEUTICALS GROUP
 
Annual Sustainability Report 2011 (PDF, 1607Kb) Annual Sustainability Report 2011  
The above sustainability report is an organizational report that will provide information about economic, environmental, social and governance performance.
   
   
  TAJ PHARMACEUTICALS GROUP FIGURE AND REPORTS
  Financial Report for FY 2011 (IFRS, audited) (PDF, 1416Kb)
  Financial Report for FY 2010 (IFRS, audited) (PDF, 868Kb)
  Financial Report for FY 2009 (IFRS, audited) (PDF, 1243Kb)
  Financial Report for FY 2008 (IFRS, audited) (PDF, 1376Kb)
  Financial Report for FY 2007 (IFRS, audited) (PDF, 1128Kb)
  Financial Report for FY 2006 (IFRS, audited) (PDF, 791Kb)
  Financial Report for FY 2005 (IFRS, audited) (PDF, 761Kb)
  Financial Report for FY 2004 (IFRS, audited) (PDF, 727Kb)
   
   
 Key analysts:
Alfa-Bank

Irina PROKOPYEVA
Phone: +7 495 795-36-55
E-mail:
iprokopyeva@alfabank.ru

Аton

Ivan NIKOLAEV
Phone: +7 495 777-66-77
E-mail:
ivan.nikolaev@aton.ru

Bank of Moscow

Vitaly Kupeev
Phone: +7 495 925-80-00
E-mail:
kupeev_vs@mmbank.ru

BCS

Maxim SHEIN
Phone: +7 495 785-53-36
E-mail:
brit@msk.bcs.ru

Vladislav METNEV
Phone: +7 495 785-53-36
E-mail:
vmetnev@msk.bcs.ru

FINAM

Eldar Vagabov
Phone: +7 495 604-82-74
E-mail:
vagabov@finam.ru

Financial Bridge

Olga SHKRED
Phone: +7 495 956-68-85
E-mail:
shkred@finbridge.ru

Goldman Sachs

Anton FARLENKOV
Phone: +7 495 645-40-19
E-mail:
anton.farlenkov@gs.com

Yulia GERASIMOVA
Phone: +7 495 645-40-00
E-mail:
yulia.gerasimova@gs.com

ING Bank

Luke POLONEKI
Phone: +44 20 7767 5851
E-mail:
Luke.Poloniecki@UK.ING.com

JP Morgan

Elena JOURONOVA
Phone: +7 495 967-38-88
E-mail:
elena.v.jouronova@jpmorgan.com

 

KIT Finance

Natalya KOLUPAEVA
Phone: +7 495 641-44-14
E-mail:
n.kolupaeva@kf.ru

Metropol

Tatiana BOBROVSKAYA
Phone: +7 495 933-33-16
E-mail:
bobrovskaya.t@metropol.ru

MDM Bank

Maria SHEVTSOVA
Phone: +7 495 795-25-21
E-mail:
maria.shevtsova@mdmbank.com

Renaissance Capital

Natalya ZAGVOZDINA
Phone: +7 495 258-77-53
E-mail:
nzagvozdina@rencap.com

Rye, Man & Gor Securities

Oleg SUDAKOV
Phone: +7 501 258-62-62
E-mail:
osudakov@rmg.ru

TKB Capital

Natalya KOLUPAEVA
Phone: +7 495 981-34-30
E-mail:
n.kolupaeva@tkbc.ru

Troika Dialog

Victoria GRANKINA
Phone: +7 495 258-05-11
E-mail:
victoria_grankina@troika.ru

Mikhail KRASNOPEROV
Phone: +7 495 258-05-11
E-mail:
mikhail_krasnoperov@troika.ru

UBS

Svetlana SUKHANOVA
Phone: +7 495 648-23-67
E-mail:
svetlana.sukhanova@ubs.com

Uralsib

Tigran HOVHANNISYAN
Phone: +7 495 785-12-12
E-mail:
hovhannisyan@uralsib.ru

Unicredit Securities

Natalia SMIRNOVA
Phone: +7 495 777-88-77, ext. 3120
E-mail:
natalian.smirnova@unicreditsec.ru

 



Note: Taj Pharmaceuticals Limited (the "Company") believes that the information included in the Investor Relations section of this website was correct at the time it was added to the website. However, the Company expressly disclaims any duty to update the information on the website and makes no representation or warranty as to accuracy and completeness of the contents of this Investors Relations section of the website or any other section of the website. Access to and use of the information on this website is at the user's own risk. The Company assumes no responsibility for any errors or omissions in the content of this website and disclaims any liability for damages of any kind (whether direct, consequential or punitive) arising out of the use of this website or the information contained on the website or on links to or from this website.

The Investor Relations section of this website contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934. All statements other than statements of historical facts, included on this website regarding the Company's strategy, expected future financial position, results of operations, cash flows, financing plans, discovery and development of products, strategic alliances, competitive position, plans and objectives of management are forward-looking statements. Words such as "anticipate," "believe," "estimate," "expect," "intend," "plan," "will" and other similar expressions help identify forward-looking statements, although not all forward-looking statements contain these identifying words. In particular, any statements regarding the Company's financial results and outlook, the continued implementation of the Company's strategic plan, the development of the Company's pipeline, the commencement of Phase 3 clinical trials for Puricase (pegloticase) are forward-looking statements. These forward-looking statements involve substantial risks and uncertainties and are based on current expectations, assumptions, estimates and projections about the Company's business and the biopharmaceutical and specialty pharmaceutical industries in which the Company operates. Such risks and uncertainties include, but are not limited to, the delay or failure in developing Puricase (pegloticase) and other product candidates; difficulties of expanding the Company's product portfolio through in-licensing or acquisition; not being able to manufacture commercial quantities of our products; not gaining market acceptance sufficient to justify development and commercialization costs if our products are approved for marketing; introduction of generic competition for API; fluctuations in buying patterns of wholesalers; potential future returns of API or other products; the Company continuing to incur substantial net losses for the foreseeable future; difficulties in obtaining financing; potential development of alternative technologies or more effective products by competitors; reliance on third-parties to manufacture, market and distribute many of the Company's products; risks of maintaining protection for the Company's intellectual property; risks of an adverse determination in any future intellectual property litigation; and risks associated with stringent government regulation of the biopharmaceutical and specialty pharmaceutical industries and other factors set forth more fully in certain reports filed with the Securities and Exchange Commission, to which investors are referred for further information. The Company may not actually achieve the plans, intentions or expectations disclosed in its forward-looking statements, and you should not place undue reliance on the Company's forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements that the Company makes. The Company's forward-looking statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, joint ventures or investments that the Company may make. The Company does not have a policy of updating or revising forward-looking statements and assumes no obligation to update any forward-looking statements.


Growing Stronger, Growing
Better

child injection
 
pharma capsule

 
 






 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 


 

 


 

 

 

 

 

 

   
   
FIGURE & REPORTS
 
 
 
 
   
   
   
  india flag
  The Taj Pharmaceuticals Limited (Taj Group) has operations in every major international market
    AFRICA
  ASIA PACIFIC
  EUROPE
  MIDDLE EAST
  THAILAND
  BANGLADESH
  NORTH AMERICA
  SOUTH AMERICA
  RUSSIA
  NEWZELAND
  UNITED KINGDOM
 

   

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 
 www.tajpharma.com

   

              
 Print page   Send by mail

About Taj

Company

Products Diseases Health Divisions Media R & D Sustainability
Figure & Reports Investors

Countries

Brochure E-mail us Export & Import
Vacancies | C & F Agency | Distributor | Group Companies | History | Enquire Form | Countries | Pharma Technology
 Contact | Sitemap | User Terms and Conditions | Privacy and Cookie Statement